JURA.Bio

JURA.Bio is a biotech company working on the next generation of cell therAPIes, pAIring synthetic biology with machine learning through a platform it calls the RedPoint design System. Rather than a consumer-facing tool, it is a research and discovery environment aimed at teams that engineer therapeutic cells and want to compress the design-build-test cycle.

What it does

The platform is positioned as an end-to-end, ML-guided discovery pipeline. According to the company, it brings together computational design and wet-lab experimentation so that candidate cell therapies can be designed, built and tested at scale. JURA also describes two therapeutic angles: an MHC-CAR APProach intended to widen the range of targets that engineered cells can address, and a cell-free system aimed at autoimmune disease by intervening in inflammatory signaling cascades.

In prACTice, this means the product sits at the interSECtion of computational biology and laboratory Operations. Users would typically interact with design tooling and data analysis layers that Inform which constructs or cell designs move forward into testing.

Key capabilities

• ML-guided design: Machine Learning models inform the selection and optimization of cell therapy candidates.
• Synthetic biology integration: computational design is coupled with construction and testing of engineered cells.
• Scaled experimentation: the workflow is framed around running large batches of designs and assays rather than one-off projects.
• Target expansion research: the MHC-CAR program explores broadening which disease targets engineered cells can reach.
• Autoimmune focus: a cell-free system is described for interrupting self-inflammation cascades.

Who it is for

JURA.Bio is relevant to translational researchers, cell therapy developers and biotech teams exploring engineered cell products or autoimmune interventions. Academic groups with cell engineering programs may also find the design-build-test framing useful, though the platform appears oriented toward organizations with laboratory capacity and drug development goals.

How to get started

There is no public self-serve signup described. Interested teams should visit the official website to review the science, then reach out through the company's contact channels to discuss partnership, collaboration or platform access. Expect an evaluation process rather than immediate onboarding.

Pricing and access caveat

Pricing is not publicly listed and likely depends on Partnership or licensing arrangements, so costs may vary by scope and organization. Product details, availability and program status are drawn from company materials and may change over time. Confirm current capabilities, access terms and commercial terms directly with JURA.Bio before planning any work around the platform.